Tom Bäck

2.5k total citations
71 papers, 2.0k citations indexed

About

Tom Bäck is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Tom Bäck has authored 71 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Radiology, Nuclear Medicine and Imaging, 33 papers in Pulmonary and Respiratory Medicine and 16 papers in Oncology. Recurrent topics in Tom Bäck's work include Radiopharmaceutical Chemistry and Applications (62 papers), Medical Imaging Techniques and Applications (25 papers) and Monoclonal and Polyclonal Antibodies Research (23 papers). Tom Bäck is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (62 papers), Medical Imaging Techniques and Applications (25 papers) and Monoclonal and Polyclonal Antibodies Research (23 papers). Tom Bäck collaborates with scholars based in Sweden, Denmark and United States. Tom Bäck's co-authors include Sture Lindegren, Holger Jensen, Lars Jacobsson, Stig Palm, Ragnar Hultborn, Per Albertsson, Håkan Andersson, Jörgen Elgqvist, Emma Aneheim and Sofia H.L. Frost and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Tom Bäck

69 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tom Bäck Sweden	28	1.8k	756	450	308	158	71	2.0k
Sture Lindegren Sweden	25	1.7k 0.9×	708 0.9×	413 0.9×	230 0.7×	154 1.0×	79	1.9k
Stig Palm Sweden	23	1.6k 0.9×	755 1.0×	431 1.0×	295 1.0×	134 0.8×	53	1.9k
Holger Jensen Sweden	23	1.4k 0.8×	604 0.8×	346 0.8×	190 0.6×	123 0.8×	62	1.6k
George Sgouros United States	25	1.6k 0.9×	786 1.0×	498 1.1×	328 1.1×	216 1.4×	44	2.0k
Roy H. Larsen Norway	32	2.5k 1.4×	1.5k 2.0×	906 2.0×	356 1.2×	181 1.1×	81	2.9k
Robert F. Hobbs United States	32	2.2k 1.2×	1.1k 1.5×	563 1.3×	773 2.5×	147 0.9×	116	2.7k
Kwamena E. Baidoo United States	29	1.4k 0.8×	642 0.8×	537 1.2×	99 0.3×	271 1.7×	51	1.8k
Robert W. Atcher United States	26	1.6k 0.9×	619 0.8×	455 1.0×	239 0.8×	360 2.3×	64	2.2k
Michel Chérel France	32	1.6k 0.9×	568 0.8×	870 1.9×	195 0.6×	557 3.5×	117	2.8k
Alain Faivre-Chauvet France	28	1.7k 1.0×	429 0.6×	720 1.6×	127 0.4×	421 2.7×	106	2.4k

Countries citing papers authored by Tom Bäck

Since Specialization

Citations

This map shows the geographic impact of Tom Bäck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Bäck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Bäck more than expected).

Fields of papers citing papers by Tom Bäck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Bäck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Bäck. The network helps show where Tom Bäck may publish in the future.

Co-authorship network of co-authors of Tom Bäck

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Bäck. A scholar is included among the top collaborators of Tom Bäck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Bäck. Tom Bäck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Haddad, Férid, et al.. (2024). Optimised solid-phase extraction of 211At: Activity balance of 211At, 210At and 210Po after wet chemistry target dissolution. Radiation Physics and Chemistry. 225. 112146–112146. 1 indexed citations

Aneheim, Emma, Tom Bäck, Holger Jensen, Stig Palm, & Sture Lindegren. (2024). A proposed production method for astatinated (At-211) Trastuzumab for use in a Phase I clinical trial. PLoS ONE. 19(9). e0307543–e0307543. 2 indexed citations

Jensen, Holger, et al.. (2023). Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211. Pharmaceuticals. 16(4). 595–595. 12 indexed citations

Albertsson, Per, Tom Bäck, Karin Bergmark, et al.. (2023). Astatine-211 based radionuclide therapy: Current clinical trial landscape. Frontiers in Medicine. 9. 1076210–1076210. 49 indexed citations

Hallqvist, Andreas, Lars Jacobsson, Per Karlsson, et al.. (2022). Estimating the Risk for Secondary Cancer After Targeted α-Therapy with²¹¹At Intraperitoneal Radioimmunotherapy. Journal of Nuclear Medicine. 64(1). 165–172. 5 indexed citations

Poulie, Christian B. M., Tom Bäck, Sture Lindegren, et al.. (2022). Covalent core-radiolabeling of polymeric micelles with ¹²⁵I/²¹¹At for theranostic radiotherapy. Nanotheranostics. 6(4). 388–399. 10 indexed citations

Fritton, J. Christopher, et al.. (2021). Radium-223–Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow. Molecular Cancer Research. 19(10). 1739–1750. 19 indexed citations

Poulie, Christian B. M., Sture Lindegren, Emma Aneheim, et al.. (2021). Surface Adsorption of the Alpha-Emitter Astatine-211 to Gold Nanoparticles Is Stable In Vivo and Potentially Useful in Radionuclide Therapy. SHILAP Revista de lepidopterología. 2(4). 196–207. 11 indexed citations

Lindegren, Sture, Per Albertsson, Tom Bäck, et al.. (2020). Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure. Cancer Biotherapy and Radiopharmaceuticals. 35(6). 425–436. 69 indexed citations

10.

Bäck, Tom, Karin Jennbacken, Sture Lindegren, et al.. (2020). Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors. EJNMMI Research. 10(1). 10–10. 26 indexed citations

11.

Levan, Kristina, et al.. (2017). Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b. BMC Cancer. 17(1). 303–303. 33 indexed citations

12.

Bäck, Tom, Tomas Ohlsson, Holger Jensen, et al.. (2014). Sequential Radioimmunotherapy with ¹⁷⁷ Lu- and ²¹¹ At-Labeled Monoclonal Antibody BR96 in a Syngeneic Rat Colon Carcinoma Model. Cancer Biotherapy and Radiopharmaceuticals. 29(6). 238–246. 7 indexed citations

13.

Delle, Ulla, et al.. (2014). Alpha particle induced DNA damage and repair in normal cultured thyrocytes of different proliferation status. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 765. 48–56. 9 indexed citations

14.

Orozco, Johnnie J., Tom Bäck, Aimee L. Kenoyer, et al.. (2013). Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. Blood. 121(18). 3759–3767. 54 indexed citations

15.

Frost, Sofia H.L., Tom Bäck, Nicolas Chouin, et al.. (2012). Comparison of ²¹¹ At-PRIT and ²¹¹ At-RIT of Ovarian Microtumors in a Nude Mouse Model. Cancer Biotherapy and Radiopharmaceuticals. 28(2). 108–114. 18 indexed citations

16.

Frost, Sofia H.L., Tom Bäck, Nicolas Chouin, et al.. (2011). In Vivo Distribution of Avidin-Conjugated MX35 and ²¹¹ At-Labeled, Biotinylated Poly- l -Lysine for Pretargeted Intraperitoneal α-Radioimmunotherapy. Cancer Biotherapy and Radiopharmaceuticals. 26(6). 727–736. 9 indexed citations

17.

Bäck, Tom, Jörgen Elgqvist, Lars Jacobsson, et al.. (2011). Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model. Nuclear Medicine and Biology. 39(1). 15–22. 34 indexed citations

18.

Lindegren, Sture, et al.. (2008). Direct Procedure for the Production of²¹¹At-Labeled Antibodies with an ε-Lysyl-3-(Trimethylstannyl)Benzamide Immunoconjugate. Journal of Nuclear Medicine. 49(9). 1537–1545. 66 indexed citations

19.

Lindegren, Sture, Tom Bäck, & Holger Jensen. (2001). Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Applied Radiation and Isotopes. 55(2). 157–160. 134 indexed citations

20.

Forssell‐Aronsson, Eva, Lars Jacobsson, Tom Bäck, et al.. (1993). Therapy with 125I-labelled internalized and non-internalized monoclonal antibodies in nude mice with human colon carcinoma xenografts. Nuclear Medicine and Biology. 20(2). 133–144. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact